Edwards Lifesciences

Rank: 28
2016 Rank36
Employees11,100
Revenue:$2,963,700,000
R&D Spend:$443,300,000
Fiscal year ending:12-31-16
Click here to see all 100

Edwards Lifesciences Receives Approval For SAPIEN 3 Valve In Japan. Edwards SAPIEN XT Valve Receives FDA Approval For Pulmonic Procedures. Edwards Receives FDA Approval For Expanded Indication Study Of SAPIEN 3 Valve. Edwards Heart Valve Pioneer Starr Receives Prestigious Scientific Honor. Edwards SAPIEN XT Valve Receives FDA Approval For Aortic Valve-In-Valve Procedures.

Big 100 Mini Logo Key Personnel: Michael Mussallem, chairman & CEO; Dirksen Lehman, corporate VP, public affairs; John McGrath, corporate VP, quality, regulatory, clinical; Katie Szyman, corporate VP, critical care; Patrick Verguet, corporate VP, EMEA, Canada and Latin America; Aimee Weisner, corporate VP, general counsel, Bernard Zovighian, corporate VP, surgical heart valve therapy; Donald Bobo Jr., corporate VP, strategy & corporate development; Christine McCauley, corporate VP, human resources; Stanton J. Rowe, corporate VP, advanced technology & chief scientific officer; Scott B. Ullem, corporate VP, CFO; Dr. Huimin Wang, corporate VP, Japan, Asia and Pacific; Larry L. Wood, corporate VP, transcatheter heart valves;

1 Edwards Way
Irvine, California
92614
USA